Physician profile
David C Haefeli
NPI 1639272636
$7,133.92
in general payments reported to CMS, 2019-2025
43 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $1,178 · 2021: $1,618 · 2022: $1,325 · 2023: $1,137 · 2024: $725 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,319.01 | 2019-2025 | |
| Lilly USA, LLC | $595.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $564.89 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $434.85 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $427.63 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $392.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $325.89 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $312.39 | 2019-2025 | |
| Abbott Laboratories | $284.58 | 2020-2025 | Freestyle Libre 3, Gallant |
| Amgen INC. | $248.78 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $207.61 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $196.82 | 2019-2023 | Livalo, Seglentis |
| Currax Pharmaceuticals LLC | $190.49 | 2020-2024 | Contrave |
| Merck Sharp & Dohme LLC | $153.39 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.63 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Haefeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.